Apogee Therapeutics Inc (APGE) - News Archive

In a significant development for the treatment of moderate-to-severe atopic dermatitis, Apogee Therapeutics, Inc. (Nasdaq: APGE) has announced the acceptance of late-breaking data from its Phase 2 APEX trial of APG777 f...

Title : Advancements in Respiratory Therapeutics: Apogee Therapeutics Doses First Participants in Phase 1 Clinical Trial of APG333 The landscape of therapeutic interventions for respiratory and inflammatory conditions h...

Revolutionizing Inflammation and Immunology: Insights from Apogee Therapeutics’ Upcoming Virtual R&D Day In an era where innovation in drug development remains pivotal, Apogee Therapeutics is poised to make significant...

Apogee Therapeutics Initiates Phase 2 Clinical Trial of APG777 for Atopic Dermatitis Following Promising Phase 1 Results Apogee Therapeutics recently announced the commencement of dosing in their Phase 2 clinical trial...

Apogee Therapeutics Advances Promising Drug Pipeline and Acknowledges Strong First Quarter 2024 Financial Performance: Anticipates Key Data Release for APG777 in Late 2025Apogee Therapeutics, a leading biopharmaceutical...

Apogee Therapeutics, a biopharmaceutical company, has announced the dosing of the first participants in a Phase 1 trial for APG808, a novel half-life extended IL-4R antibody. This antibody is being investigated for its...

Apogee Therapeutics, Inc., a clinical-stage biotechnology company focused on developing cutting-edge biologics for various inflammatory and immunology indications, proudly announced the completion of an upsized public o...

Apogee Therapeutics Announces Upsized Public Offering, Raising $420 Million for Biologics DevelopmentSan Francisco and Waltham, Mass., March 07, 2024 - Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechn...

Apogee Therapeutics, Inc. Seeks Funding for Biologics Development Through Public OfferingSAN FRANCISCO and WALTHAM, Mass., March 05, 2024 Apogee Therapeutics, Inc. (Nasdaq: APGE), a leading clinical-stage biotechnology...

Apogee Announces Promising Interim Results from Phase 1 Trial for APG777: A Breakthrough in the Treatment of Inflammatory DiseasesApogee Pharmaceuticals, a leading biotech company, has reported positive interim results...